Roche to Present New Alzheimer's Disease Data at CTAD 2026, Highlighting Multi-pronged Approach
Roche announced it will present new data from its Alzheimer’s disease portfolio at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Congress in Boston, MA, from November 16–19, 2026. The company plans to showcase 16 accepted abstracts, including two scientific symposia and two oral presentations. A key highlight is the initiation of a new Phase II clinical trial, TARBELA-AD, which will evaluate RG6434, an investigational oral NLRP3 inhibitor, for early symptomatic Alzheimer’s disease. This trial signifies Roche's strategy to target neuroinflammation, alongside its ongoing efforts to address amyloid aggregation with candidates like trontinemab. Dr. Levi Garraway, Roche’s Chief Medical Officer, emphasized the need for multifaceted strategies to combat the complexity of Alzheimer's. Additionally, Roche's diagnostics division will present data on its blood-based biomarker portfolio, including the FDA-cleared Elecsys pTau217 and Elecsys pTau181 tests, aimed at enabling earlier and more accurate diagnosis.
